Keywords: Valeant, Zovirax, GlaxoSmithKline, USA, Canada, Anti-viral

Valeant buys US/Canadian rights to GlaxoSmithKline’s Zovirax for $300 million

Article | 04 February 2011

Canada-based Valeant Pharmaceuticals International (NYSE: VRX; TSX: VRX) says that its subsidiary, Biovail Laboratories International has signed agreements to acquire ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

GlaxoSmithKline

Valeant Pharmaceuticals

Go to company listing

Related Drugs

Zovirax

Go to drug listing